Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Gyre Therapeutics ( (GYRE) ) just unveiled an update.
On August 5, 2025, Gyre Therapeutics appointed Ping Zhang as Interim CEO following the resignation of Dr. Han Ying, who transitioned to a scientific leadership role. The company reported a net income of $1.6 million for Q2 2025 and reaffirmed its full-year revenue guidance. Gyre is progressing with its pipeline, including a pivotal Phase 3 trial of Hydronidone for CHB-associated liver fibrosis and the launch of Etorel in the PRC. The leadership change is expected to strengthen Gyre’s global expansion and accelerate its delivery of transformative therapies.
The most recent analyst rating on (GYRE) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Gyre Therapeutics stock, see the GYRE Stock Forecast page.
Spark’s Take on GYRE Stock
According to Spark, TipRanks’ AI Analyst, GYRE is a Neutral.
The overall score reflects a mixed financial performance with strong corporate event news. However, technical indicators and high valuation present challenges. The recent Phase 3 trial success is a positive catalyst, but financial and technical concerns limit the stock’s attractiveness.
To see Spark’s full report on GYRE stock, click here.
More about Gyre Therapeutics
Gyre Therapeutics is a commercial-stage biopharmaceutical company focused on developing fibrosis-first therapies for chronic diseases affecting various organ systems. The company is actively expanding its commercial footprint and advancing its pipeline, with products like Hydronidone and Etorel targeting liver fibrosis and fibrosing ILD, respectively.
Average Trading Volume: 219,630
Technical Sentiment Signal: Sell
Current Market Cap: $649.4M
For an in-depth examination of GYRE stock, go to TipRanks’ Overview page.